Skip to main navigation
Skip to search
Skip to main content
Discovery - the University of Dundee Research Portal Home
Home
Profiles
Research units
Research Outputs
Projects
Datasets
Theses
Activity
Press/Media
Research Facilities
Prizes
Search by expertise, name or affiliation
Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis
Iram Haq
, Maryam Almulhem
, Simone Soars
,
David Poulton
, Malcolm Brodlie (Lead / Corresponding author)
Research output
:
Contribution to journal
›
Review article
›
peer-review
20
Citations (Scopus)
184
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Genotype
100%
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Precision Medicine
100%
Ivacaftor
37%
Tezacaftor
25%
Elexacaftor
25%
Multidisciplinary Team
12%
Randomized Trial
12%
Significant Benefit
12%
Epithelium
12%
Clinical Trials
12%
Lung
12%
Pathophysiology
12%
Autosomal Recessive
12%
Small Molecules
12%
Clinical Problems
12%
Ion Channels
12%
Equitable Access
12%
Apical Surface
12%
Monotherapy
12%
Disease Variants
12%
Gastrointestinal Tract
12%
Future Therapeutics
12%
Therapeutic Approaches
12%
Malabsorption
12%
Multisystem Disease
12%
Downstream Effects
12%
Airway Clearance
12%
Incremental Improvement
12%
Genetics Problem
12%
Recessive Genetic Conditions
12%
Medicine and Dentistry
Cystic Fibrosis
100%
Personalized Medicine
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Ivacaftor
37%
Tezacaftor
25%
Clinical Trial
12%
Infection
12%
Pathophysiology
12%
Autosomal Recessive Inheritance
12%
Ion Channel
12%
Monotherapy
12%
Gastrointestinal Tract
12%
Regulator Gene
12%
Systemic Disease
12%
Malabsorption
12%
Lung Clearance
12%
Lung
12%
Diseases
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Cystic Fibrosis Transmembrane Conductance Regulator
100%
Ivacaftor
37%
Tezacaftor
25%
Clinical Trial
12%
Pathophysiology
12%
Infection
12%
Ion Channel
12%
Monotherapy
12%
Systemic Disease
12%
Malabsorption
12%
Diseases
12%